leisure time -WSS

leisure time

author：knowledge 2025-09-29 18:17:01 - browse：318

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Federal weight loss drug coverage is 30 years out of date

leisure time

WSS

The biotech scorecard for Q1: 17 stock

Chronically ill young patients struggle to find fertility info

Antibiotic resistance and the global rise in human conflict

A single drug, study failures leave Anavex with nothing but cash

NYU Langone launches private ChatGPT for its health care data

New weight loss drugs work. But how can they best be used?

focus

leisure time

focus

Heart attack and stroke risk calculators need revising

Burning questions for the 2024 JPM Healthcare Conference

Alkermes shareholders re

Neuroscience startup Neumora files for IPO

Hepatitis C has a cure — but many Americans still lack access to it

JPM: CVS says Medicare Advantage patients are impacting profits

Tori Bowie and the unacceptable rates of Black maternal death

How a symptom of dementia informs our understanding of creativity

Duchenne breakthrough therapy leaves behind pioneering families

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

leisure time

Morgan Health, with ambitious aims, wants you to know it’s still here

White House finalizes ITC's import ban of latest Apple Watches

As pharma fights Medicare drug negotiation, hospitals, docs silent

A single drug, study failures leave Anavex with nothing but cash

The biotech scorecard for Q1: 17 stock

CDC advisory panel says seniors 'may' get RSV vaccine

leisure time

leisure time

Wikipedia

knowledge